Large TAILORx Outcomes Study Demonstrates 99% of Patients with Low Oncotype DX® Recurrence Score® Results Were Breast Cancer Relapse-Free following Five Years of Hormone Therapy Alone
GENEVA, Switzerland, [September 28, 2015] – Genomic Health today announced the presentation of the first results1 from the Trial Assigning…